Is BPC-157 approved or proven in humans?

No. It has not been approved by any regulator and has not been tested in controlled human trials. The published evidence is preclinical. We supply it for laboratory research only.

What has BPC-157 research looked at?

Cell and rodent studies of tissue repair, blood-vessel formation and cell migration, together with review articles. Much of the primary work is from one group, and independent reviewers note that human efficacy is unconfirmed. The cited studies are listed above.

A synthetic fifteen-amino-acid peptide, sequence GEPPPGKPADDAGLV, studied in preclinical models.

BPC-157 research: what the studies have looked at

This page summarises the published research on BPC-157, for reference. It states what each study investigated and in what model, not an effect in people, and it is not medical advice. BPC-157 has not been approved as a medicine anywhere and has not been tested in controlled human trials; what we supply is a research chemical for laboratory use only.

What BPC-157 is

BPC-157 is a synthetic peptide of fifteen amino acids, the sequence GEPPPGKPADDAGLV, described by the group that first reported it as related to a protein found in gastric juice. Almost all of the published work is preclinical, in cells and in rodents. Two things about the evidence are worth stating plainly before the studies: there are no published randomised human trials, and a large share of the primary work comes from a single research group, a limit that independent reviewers have themselves noted.

What the studies investigated

Chang et al. (2011), Journal of Applied Physiology 110(3):774-780. In vitro tendon fibroblasts and rat. Investigated cell outgrowth and migration and reported involvement of the FAK-paxillin pathway (an independent group) Source.

Gwyer, Wragg and Wilson (2019), Cell and Tissue Research 377(2):153-159. Independent review. Reviewed the tendon and ligament literature and noted that human efficacy remains unconfirmed Source.

Sikirić et al. (2020), Gut and Liver 14(2):153-167. Preclinical review. Reviewed reported gastrointestinal and organ-protective effects in animal models (the originating group) Source.

Mechanism, as described in the literature

The mechanisms proposed in the literature include effects on new blood-vessel formation, via VEGF signalling, and on cell migration, via the FAK-paxillin pathway, reported mainly in tissue and rodent models of injury. These are hypotheses supported by animal data, not established human effects. On the US regulatory side, BPC-157 has been placed on the FDA’s 503A interim list in the category of substances that raise safety or quality concerns for compounding; that listing has been under review, so anyone relying on it should check the current version.

The material we supply

We supply BPC-157 as a research chemical, released against a written specification with a batch certificate of analysis. It is not a medicine and is not for human or animal use. For the vial sizes, the price per mg and how to order, see where to buy BPC-157 wholesale; the COA lookup pulls the certificate for any batch. The references above link to each study’s record; this summary is for research and educational reference only.